Study protocol for a randomized controlled trial with rituximab for psychotic disorder in adults (RCT-Rits).

ABSTRACT:

Background

The role of inflammation in the aetiology of schizophrenia has gained wide attention and research on the association shows an exponential growth in the last 15 years. Autoimmune diseases and severe infections are risk factors for the later development of schizophrenia, elevated inflammatory markers in childhood or adolescence are associated with a greater risk of schizophrenia in adulthood, individuals with schizophrenia have increased levels of pro-inflammatory cytokines compared to healthy controls, and autoimmune diseases are overrepresented in schizophrenia. However, treatments with anti-inflammatory agents are so far of doubtful clinical relevance. The primary objective of this study is to test whether the monoclonal antibody rituximab, directed against the B-cell a

SUBMITTER: Bejerot S 

PROVIDER: S-EPMC10594806 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature